AIM ImmunoTech Inc

AIM ImmunoTech Inc. issued a stockholder letter from Chief Executive Officer Thomas Equels positioning its drug Ampligen as a potential complement to daraxonrasib following the U.S. Food and Drug Administration's recent approval of daraxonrasib for metastatic pancreatic cancer. The letter notes that a pivotal randomized study showed daraxonrasib achieved median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, an improvement of 6.5 months, but that many patients on both treatments still experience disease progression and mortality. Ampligen, a TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment, has a different mechanism of action from daraxonrasib, which selectively inhibits RAS. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months versus 12.5 months in well-matched historical controls, an observed increase of 22.3 months. AIM also said its ongoing Phase 2 DURIPANC trial is evaluating Ampligen with AstraZeneca's durvalumab in patients whose pancreatic cancer was stable post-FOLFIRINOX, with topline results anticipated in Q1 2027 and a detailed overall survival analysis in Q3 2027.

AIM ImmunoTech has completed the final dose of Ampligen in its Phase 2 DURIPANC trial for metastatic pancreatic cancer ahead of schedule. The primary endpoint analysis for clinical benefit rate is expected to begin in December 2026 with topline results in the first quarter of 2027, while the overall survival analysis is anticipated to start in June 2027. The trial combines Ampligen with AstraZeneca's Imfinzi and is conducted in collaboration with Erasmus Medical Center. The company previously reported a median overall survival of 34.8 months in a subset of patients from a Dutch Named Patient Program, compared to 12.5 months for historical controls.

AIM ImmunoTech released a new CEO Corner segment in which Chief Executive Officer Thomas Equels discussed the company's growing momentum in pancreatic cancer and the milestones positioning Ampligen for its next development stage. Equels highlighted the urgent unmet need in pancreatic cancer, reviewed progress in the DURIPANC Phase 2 clinical program evaluating Ampligen in combination with AstraZeneca's Imfinzi, and noted that AIM believes it is entering one of the most catalyst-rich periods in its history. Topics included the successful completion of patient enrollment and dosing in DURIPANC, encouraging interim clinical observations, continued favorable safety findings, ongoing Phase 3 planning, the strategic collaboration with AstraZeneca and Erasmus Medical Center, expansion of AIM's intellectual property portfolio, and the broader potential of Ampligen to overcome resistance in immunologically cold tumors.

AIM ImmunoTech has completed enrollment ahead of schedule in its Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer, with topline results expected in the first quarter of 2027. The company reported positive interim clinical updates and a favorable safety profile, and it is advancing regulatory planning toward a potential pivotal program. Key upcoming milestones include a primary endpoint analysis anticipated to begin in December 2026 and secondary endpoint assessments expected in June 2027. AIM has also strengthened its intellectual property portfolio and balance sheet through multiple financing transactions. Management believes the next twelve months represent a potentially transformative value-creation opportunity centered on one of the largest unmet needs in cancer treatment.